3 citations
,
October 2013 in “Photodermatology Photoimmunology & Photomedicine” The treatment is a safe and effective option for hair regrowth in patchy alopecia areata.
19 citations
,
June 2020 in “BMC Cancer” Trichilemmal carcinoma shares genetic changes with other skin cancers, suggesting similar causes and potential treatments.
May 2023 in “Research Square (Research Square)” The HDDPiW-jSB solution may prevent hair loss caused by docetaxel in rats when applied regularly.
1 citations
,
June 2023 in “Sciential - McMaster Undergraduate Science Journal” Scalp cooling effectively prevents hair loss in breast cancer patients undergoing chemotherapy.
January 2017 in “Elsevier eBooks” Radiation therapy for cancer often causes skin problems like redness, dryness, and pain.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
April 2020 in “Research Square (Research Square)” Trichilemmal carcinoma shares genetic traits with other skin cancers, suggesting similar treatment options.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
25 citations
,
April 2010 in “Clinical and Experimental Dermatology” Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
5 citations
,
January 2013 in “Journal der Deutschen Dermatologischen Gesellschaft” The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
54 citations
,
September 2019 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
3 citations
,
August 2019 in “JAAD Case Reports” Temporary hair loss can occur after 5-fluorouracil treatment for keloids.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
May 2018 in “Dermatologic Surgery” 102 citations
,
October 2010 in “Molecular Pharmaceutics” Copper-doxorubicin nanoparticles effectively treat tumors with less toxicity.
97 citations
,
September 2006 in “Pharmaceutical Research” No treatment fully prevents hair loss from chemotherapy yet.
15 citations
,
January 1989 in “European Journal of Cancer and Clinical Oncology”
1 citations
,
October 2023 in “Life science alliance” Pantethine may boost the immune system's ability to fight sarcoma.
July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
1 citations
,
October 2025 in “Ophthalmology Science” Lower doses of topotecan are safe for eyes, but higher doses may harm the retina.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
25 citations
,
February 2017 in “Anticancer Research/Anticancer research” Ozone therapy might improve cancer treatment and reduce its side effects.
3 citations
,
June 2011 in “Korean Journal of Clinical Oncology” The document concluded that there were no effective ways to prevent hair loss from chemotherapy but treatments were being explored.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
7 citations
,
July 2020 in “Pigment cell & melanoma research” RT1640 treatment reverses gray hair and promotes hair growth in mice.